Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 7/20 | 0.36 |
| ▸ | CDK7 | P50613 | 6/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17547824 | 0.91 | KDM5B (0.41) | KDM5BCDK13CDK7CDK12PLAT | |
| SCHEMBL17547814 | 0.90 | PLAT (0.37) | KDM5BPLATADAM10MMP2KDM5A | |
| SCHEMBL17547815 | 0.87 | NAMPT (0.36) | KDM5BPLATJAK1JAK2JAK3 | |
| SCHEMBL17547817 | 0.86 | PLAT (0.39) | KDM5BPLATKDM5A | |
| SCHEMBL16092544 | 0.85 | KDM5B (0.42) | KDM5BCDK13CDK7CDK12PLAT | |
| SCHEMBL16092288 | 0.82 | PLAT (0.38) | KDM5BPLATKDM5A | |
| SCHEMBL16092287 | 0.80 | PLAT (0.37) | KDM5BPLATKDM5ANAMPT | |
| SCHEMBL17547843 | 0.78 | PLAT (0.40) | KDM5BPLATKDM5A | |
| SCHEMBL16092399 | 0.78 | TBK1 (0.37) | KDM5BPLATKDM5A | |
| SCHEMBL16092289 | 0.77 | PLAT (0.35) | KDM5BPLATKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5B 3/4885CDK13 1778/4885CDK7 644/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5B 3/4885CDK13 1778/4885CDK7 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.